AKT1 and breast cancer: This study confirmed that SC66 exerts its anti‐BC effect in vivo and in vitro through the AKT/β‐catenin signalling pathway, specifically including inhibiting EMT‐mediated metastasis, inducing cell cycle redistribution and promoting tumour cell apoptosis.